Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZNCF) EBIAT (2016 - 2025)

Historic EBIAT for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.3 billion.

  • Astrazeneca's EBIAT rose 5526.67% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.2 billion, marking a year-over-year increase of 4533.45%. This contributed to the annual value of $10.2 billion for FY2025, which is 4533.45% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's EBIAT is $2.3 billion, which was up 5526.67% from $2.5 billion recorded in Q3 2025.
  • Astrazeneca's EBIAT's 5-year high stood at $2.9 billion during Q1 2025, with a 5-year trough of -$1.7 billion in Q3 2021.
  • Its 5-year average for EBIAT is $1.3 billion, with a median of $1.5 billion in 2021.
  • In the last 5 years, Astrazeneca's EBIAT plummeted by 35360.98% in 2021 and then surged by 40555.56% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's EBIAT stood at -$346.0 million in 2021, then surged by 360.69% to $902.0 million in 2022, then rose by 6.32% to $959.0 million in 2023, then skyrocketed by 56.41% to $1.5 billion in 2024, then skyrocketed by 55.27% to $2.3 billion in 2025.
  • Its last three reported values are $2.3 billion in Q4 2025, $2.5 billion for Q3 2025, and $2.4 billion during Q2 2025.